CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases

Drug News and Perspectives

Volumn 19, Issue 6, 2006, Pages 325-328

  Soos, Timothy J ^a   Meijer, Laurent ^b   Nelson, Peter J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INDIRUBIN; PROTEIN SERINE KINASE; ROSCOVITINE;

ANTIINFLAMMATORY ACTIVITY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; GLOMERULOPATHY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY CELL; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RESEARCH; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROLIFERATIVE GLOMERULONEPHRITIS; PROLIFERATIVE RENAL DISEASE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KIDNEY DISEASES; PROTEIN KINASE INHIBITORS;

EID: 33748779578     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.6.985939     Document Type: Review

References (30)

1. Pabst, R. and Sterzel, R.B. Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int 1983, 24: 626-31.
2. Nadasdy, T., Laszik, Z., Blick, K.E. et al. Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 1994, 4: 2032-9.
3. Shankland, S.J. Cell-cycle control and renal disease. Kidney Int 1997, 52: 294-308.
4. Nelson, P.J. and Shankland, S.J. Therapeutics in renal disease: the road ahead for antiproliferative targets. Nephron Exp Nephrol 2006, 103: e6-e15.
5. Leclerc, S., Garnier, M., Hoessel, R. et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001, 276: 251-60.
6. Knockaert, M., Greengard, P. and Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Scei 2000, 23: 417-25.
7. Malumbres, M. and Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005, 30: 630-41.
8. Meijer, L., Flajolet, M. and Greengard, P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004, 25: 471-80.
9. Jope, R.S. and Johnson, G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29: 95-102.
10. Senderowicz, A.M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004, 16: 670-8.
11. Tipping, P.G. and Kitching, A.R. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol 2005, 142: 207-15.
12. Roshak, A., Jackson, J.R., Chabot-Fletcher, M. et al. Inhibition of NFkappaB-mediated interleukin-1 beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine. J Pharmacol Exp Ther 1997, 283: 955-61.
13. Breton, J.J. and Chabot-Fletcher, M. The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear faclor-kappaB. J Pharmacol Exp Ther 1997, 282: 459-66.
14. Badger, A.M., Cook, M.N., Swift, B.A. et al. Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine. J Pharmacol Exp Ther 1999, 290: 587-93.
15. Sharma, V., Lansdell, T.A., Jin, G. et al. Inhibition of cytokine production by hymenialdisine derivatives. J Med Chem 2004, 47: 3700-3.
16. Takada, Y. and Aggarwal, B.B. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004, 279: 4750-9.
17. Kunikata, T., Tatefuji, T., Aga, H. et al. Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity. Eur J Pharmacol 2000, 410: 193-200.
18. Mak, N.K., Leung, C., Wei, X. et al. Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells. Biochem Pharmacol 2004, 67: 167-74.
19. Berg, E.L., Hytopoulos, E., Plavec, I. et al. Approaches to the analysis of cell signaling networks and their application in drug discovery. Curr Opin Drug Discov Devel 2005, 8: 107-14.
20. Berg, E.L., Kunkel, E.J., Hytopoulos, E. et al. Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol Methods 2006, 53: 67-74.
21. Martin, M., Rehani, K., Jope, R.S. et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6: 777-84.
22. Woodgett, J.R. and Ohashi, P.S. GSK3: An in-Toll-erant protein kinase? Nat Immunol 2005, 6: 751-2.
23. Pippin, J.W., Qu, Q., Meijer, L. et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997, 100: 2512-20.
24. Haraguchi, M., Okamura, M., Konishi, M. et al. Anti-angiogenic compound (TNP-470) inhibits mesangial cell proliferation in vitro and in vivo. Kidney Int 1997, 51: 1838-46.
25. Nelson, P.J., D'Agati, V.D., Cries, J.M. et al. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J Antimicrob Chemother 2003, 51: 921-9.
26. Gherardi, D., D'Agati, V., Chu, T.H. et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004, 15: 1212-22.
27. Griffin, S.V., Krofft, R., Pippin, J.W. et al. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int 2005, 67: 977-86.
28. Zoja, C., Conti, S., Daniela, C. et al. R-roscovitine (CYC202), a cyclin-dependent kinase inhibitor, reduces autoimmune renal injury and prolongs life in murine lupus nephritis. J Am Soc Nephrol, 2005, 15: 686A.
29. Sheryanna, A.M., Smith, J., Barnett, A. et al. Cyclin dependent kinase inhibitor CYC202 ameliorates experimental crescentic glomerulonephritis. J Am Soc Nephrol 2005, 15: 688A.
30. Milovanceva-Popovska, M., Kunter, U., Ostendorf, T. et al. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int 2005, 67: 1362-70.